PHS
ACHN

Pekin Hardy Strauss’s Achillion Pharmaceuticals ACHN Stock Holding History

Pekin Hardy Strauss’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,000
Closed -$110K – 252
2014
Q3 		$110K Buy
11,000
+500
+5% +$4.64K 0.02% 136
2014
Q2 		$79K Buy
+10,500
New +$41.9K 0.01% 138

Other funds holding ACHN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pekin Hardy Strauss's ACHN Position: Q4 2014 in Review

Pekin Hardy Strauss sold out of Achillion Pharmaceuticals (ACHN) in Q4 2014, closing a stake of 11,000 shares — an estimated $110K sold.

Pekin Hardy Strauss first reported a position in ACHN in Q2 2014 and held it in 2 quarters. The position peaked at $110K in Q3 2014. 179 funds tracked by Wall St. Rank hold ACHN as of Q4 2014.

  • Pekin Hardy Strauss reported no remaining Achillion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Pekin Hardy Strauss sold 11,000 Achillion Pharmaceuticals shares in Q4 2014, an estimated $110K.
  • Pekin Hardy Strauss first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Pekin Hardy Strauss's Achillion Pharmaceuticals position peaked at $110K in Q3 2014.
  • 179 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2014.

Based on Pekin Hardy Strauss's 13F filing for Q4 2014, filed 13 Feb 2015.